2021 annual financial data
INmune Bio 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was -15,748.07%.
Operating income was -29,153,000 USD and net income was -30,340,000 USD.
Operating cash flow was -28,504,000 USD.
Get free INmune Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 181,000 USD
- Operating income
- -29,153,000 USD
- Net income
- -30,340,000 USD
- Operating cash flow
- -28,504,000 USD